Aspergillus - Classification and antifungal susceptibilities

Current Pharmaceutical Design

Volumn 19, Issue 20, 2013, Pages 3615-3628

  Buzina, Walter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antifungals; Antimycotic drugs; Aspergillus; Susceptibility

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS ACULEATUS; ASPERGILLUS ALABAMENSIS; ASPERGILLUS ALLIACEUS; ASPERGILLUS BRASILIENSIS; ASPERGILLUS CAESIELLUS; ASPERGILLUS CALIDOUSTUS; ASPERGILLUS CARNEUS; ASPERGILLUS CHEVALIERI; ASPERGILLUS CLAVATUS; ASPERGILLUS DEFLECTUS; ASPERGILLUS FLAVIPES; ASPERGILLUS FLAVUS; ASPERGILLUS FOETIDUS; ASPERGILLUS FUMIGATIAFFINIS; ASPERGILLUS FUMIGATUS; ASPERGILLUS FUMISYNNEMATUS; ASPERGILLUS GRANULOSUS; ASPERGILLUS JANUS; ASPERGILLUS JAPONICUS; ASPERGILLUS LENTULUS; ASPERGILLUS NIDULANS; ASPERGILLUS NIGER; ASPERGILLUS NIVEUS; ASPERGILLUS NOMIUS; ASPERGILLUS OCHRACEUS; ASPERGILLUS ORYZAE; ASPERGILLUS REPENS; ASPERGILLUS SCLEROTIORUM; ASPERGILLUS SYDOWII; ASPERGILLUS TAMARII; ASPERGILLUS TERREUS; ASPERGILLUS TETRAZONUS; ASPERGILLUS THERMOMUTATUS; ASPERGILLUS TUBINGENSIS; ASPERGILLUS UNGUIS; ASPERGILLUS USTUS; ASPERGILLUS VERSICOLOR; ASPERGILLUS VIRIDINUTANS; DRUG ISOLATION; GENUS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FLUCYTOSINE; HUMANS;

EID: 84878664642     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319200005     Document Type: Article

References (161)

1. Zohary M. Pflanzen der Bibel. Stuttgart: Calwer Verlag 1983.
2. Micheli PA. Nova plantarum genera. Florence: Paperini 1729.
3. Bennett JW. Aspergillus: a primer for the novice. Med Mycol 2009; 47 (Suppl 1): S1-S8.
4. Gibbons JG, Salichos L, Slot JC, et al. The Evolutionary Imprint of Domestication on Genome Variation and Function of the Filamentous Fungus Aspergillus oryzae. Current Biology 2012; 22:1403-9.
5. Fresenius G. Beiträge zur Mykologie. Frankfurt a.M.: 1896: 81-82.
6. Samson RA, Varga J. Molecular Systematics of Aspergillus and its Teleomorph. In: Masayuki Machida Katsuya Gomi Eds.: Aspergillus: Molecular Biology and Genomics. Norwich: Caister Academic Press 2010.
7. Norvell LL. Fungal nomenclature. 1. Melbourne approves a new code. Mycotaxon 2011; 116: 481-90.
8. Geiser DM, Gueidan C, Miadlikowska J, et al. Eurotiomycetes: Eurotiomycetidae and Chaetothyriomycetidae. Mycologia 2006; 98: 1053-65.
9. Houbraken J, Samson RA. Phylogeny of Penicillium and segregation of Trichocomaceae into three families. Stud Mycol 2011; 70: 1-51.
10. Bennett JW. An Overview of the Genus Aspergillus. In: Masayuki Machida Katsuya Gomi (Hrsg): Aspergillus: Molecular Biology and Genomics. Norwich: Caister Academic Press 2010.
11. de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of Clinical Fungi, 3rd ed. Utrecht: CBS-KNAW Fungal Biodiversity Center 2011.
12. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161-72.
13. Stevens DA. Introduction. In: Latgé J-P, Steinbach WJ Eds.: Aspergillus fumigatus and Aspergillosis. Washington DC: ASM Press 2009.
14. Gold W, Stout HA, Pagano JF, et al. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot Annu 1955; 3: 579-86.
15. Raper KB, Fennell DI. 1965 The genus Aspergillus. Baltimore: Williams and Wilkins 1965.
16. Samson RA, Hong S, Peterson SW, Frisvad JC, Varga J. Polyphasic taxonomy of Aspergillus section Fumigati and its teleomorp Neosartorya. Stud Mycol 2007; 59: 147-203.
17. Serrano R, Gusmão L, Amorim A, Araujo R. Rapid identification of Aspergillus fumigatus within the section Fumigati. BMC Microbiol 2011; 11: 82-8.
18. Helmi M, Love RB, Welter D, Cornwell R, D Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123: 800-8.
19. Chakrabarti A, Denning DW, Ferguson BJ, et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope 2009; 119: 1809-18.
20. Haas DU, Reinthaler FF, Wüst C, Skofitsch, G, Degenkolb T, Marth E. Emission of moulds and xerophilic fungi in the immediate surroundings of composting facilities. Gefahrst Reinhalt Luft 1999; 59: 115-21.
21. Arabatzis M, Kambouris M, Kyprianou M, et al. Polyphasic Identification and Susceptibility to Seven Antifungals of 102 Aspergillus Isolates Recovered from Immunocompromised Hosts in Greece. Antimicrob Agents Chemother 2011; 55: 2025-30.
22. Latgé J-P, Steinbach WJ Eds. Aspergillus fumigatus and Aspergillosis. Washington DC: ASM Press 2009.
23. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez Tudela JL. Aspergillus section Fumigati: Antifungal susceptibility pattern and sequence-based identification. Antimicrob Agents Chemother 2008; 52: 1244-51.
24. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4: 625-32.
25. Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009; 49: 102-11.
26. Sugui JA, Vinh DC, Nardone G, et al. Neosartorya udagawae (Aspergillus udagawae), an emerging agent of aspergillosis: how different is it from Aspergillus fumigatus? J Clin Microbiol 2010, 48: 220-28.
27. Posteraro B, Mattei R, Trivella F, et al. Uncommon Neosartorya udagawae fungus as a causative agent of severe corneal infection. J Clin Microbiol 2011; 49: 2357-60.
28. Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol 2005; 43: 5996-9.
29. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J ClinMicrobiol 2003; 41:3623-6.
30. Guinea J, Peláez T, Alcalá L, Ruiz-Serrano MJ, Bouza E. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air hospital air and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 2005; 49: 3495-7.
31. Klaassen CH, Gibbons JG, Fedorova ND, Meis JF, Rokas A. Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol Ecol 2012; 21: 57-70.
32. Verweij PE, Mellado E, Melchers WJG. Multiple-triazole-resistant Aspergillosis. New Engl J Med 2007; 356: 1481-3.
33. Werff PJ van der. Longaandoeningen veroorzaakt door schimmels. Ned Tijdschr Geneesk 1951; 95: 1682-90.
34. Yasin A, Maher A, Moawad MH. Otomycosis: a survey in the eastern province of Saudi Arabia. J Laringol Otol 1978; 92: 869-76.
35. Opal SM, Asp AA, Cannady PB, Morse PL, Burton LJ, Hammer PG. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. J Infect Dis 1986; 153: 634-7.
36. Riddle HFV, Channell S, Blyth W, et al. Allergic alveolitis in a maltworker. Thorax 1968; 23: 271-80.
37. Grant IW, Blackadder ES, Greenberg M, Blyth W. Extrinsic allergic alveolitis in Scottish maltworkers Br Med J 1976; 1(6008): 490-3.
38. Batista AC, Maia H da S, Alecrim IC. Onicomicose produzida por Aspergillus clavato-nanica n. sp. An Fac Méd Recife 1955; 15: 197-203.
39. Carrillo-Muñoz AJ, Quindós G, Tur C. Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex Amphotericin B and Fluconazole. Chemotherapy 2000; 46: 235-44.
40. Varga J, Frisvad JC, Kocsubé S, et al. New and revisited species in Aspergillus section Nigri. Stud Mycol 2011; 69: 1-17.
41. Brasch J, Varga J, Jensen JM, Egberts F, Tintelnot K. Nail infection by Aspergillus ochraceopetaliformis. Med Mycol 2009; 47: 658-62.
42. Bassiouny A, Maher A, Bucci TJ, Moawad MK, Hendawy DS. Non invasive antromycosis (diagnosis and treatment). J Laringol Otol 1982; 96: 215-28.
43. Hubka V, Kubatova A, Mallatova N, et al. Rare and new etiological agents revealed among 178 clinical Aspergillus strains obtained from Czech patients and characterized by molecular sequencing. Med Mycol 2012; 50: 601-10.
44. Samson RA, Hong SB, Frisvad JC. Old and new concepts of species differentiation in Aspergillus. Med Mycol 2006, 44: S133-48.
45. García-Martos P, García-Agudo L, Gutiérrez-Calzada J, Ruiz-Aragón J, Saldarreaga A, Marín P. Actividad in vitro de anfotericina B, itraconazol y voriconazol frente a 20 especies de Aspergillus empleando el método de microdilución. Sensititre Enferm Infecc Microbiol Clin 2005; 23: 15-8.
46. Wildfeuer A, Seidl HP, Paule I, Habereiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B, and griseofulvin. Mycoses 1998; 41: 309-19.
47. Varga J, Frisvad JC, Samson RA. Two new aflatoxin producing species, and an overview of Aspergillus section Flavi. Stud Mycol 2011; 69: 57-80.
48. Geiser DM, Dorner JW, Horn BW, Taylor JW. The phylogenetics of mycotoxin and sclerotium production in Aspergillus flavus and Aspergillus oryzae. Fungal Gen Biol 2000; 31: 169-79.
49. Horn BW, Moore GG, Carbone I. Sexual reproduction in Aspergillus flavus. Mycologia 2009; 101: 423-9.
50. Koenig H, Bièvre C, de Waller J, Conraux C. Aspergillus alliaceus agent d'otorrhée chronique. Bull Soc Fr Mycol Méd 1985; 14: 85-7.
51. Washburn RG, Kennedy DW, Begley MG, Henderson DK, Bennett JE. Chronic fungal sinusitis in apparently normal hosts. Medicine 1988; 67: 231-247.
52. Degos R, Segretain G, Badillet G, Maisler A. Aspergillose de la paupière. Bull Soc Fr Derm Syph 1970; 77: 732-4.
53. Kredics L, Varga J, Kocsubé S, et al. Case of keratitis caused by Aspergillus tamarii. J Clin Microbiol 2007; 45: 3464-7.
54. Kristensen L, Stenderup J, Otkjaer A. Onychomycosis due to Aspergillus tamarii in a 3-year-old boy. Acta Derm Venereol 2005; 85: 261-2.
55. Pitt JI. Toxigenic fungi: which are important? Med Mycol 2000; 38: 17-22.
56. Manikandan P, Varga J, Kocsubé S, et al. Mycotic keratitis due to Aspergillus nomius. J Clin Microbiol 2009; 47: 3382-5.
57. Zotti M, Machetti M, Persi A, Barabino G, Parodi A. Onychomycosis: first case due to Aspergillus nomius. Acta Derm Venereol 2011; 91: 591-2.
58. Caira M, Posteraro B, Sanguinetti M, de Carolis E, Leone G, Pagano L. First case of breakthrough pneumonia due to Aspergillus nomius in a patient with acute myeloid leukemia. Med Mycol 2012; 50: 746-50.
59. Odds FC, Gerven FV, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42: 282-8.
60. Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001; 45: 124-8.
61. Seo K, Akiyoshi H, Ohnishi Y. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus. Microbiol Immunol 1999; 43: 1017-25.
62. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 2001; 45: 1456-62.
63. Gomez-Lopez A, Garcia-Effron G, Mellado E, Monzon A, Rodriguez-Tudela JL, Cuenca-Estrella M. In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 3085-8.
64. Sutton DA, Sothergill QA, Rinaldi MF. Aspergillus in vitro antifungal susceptibility data: new millennium trends. In: Advances Against Aspergillosis, Medical Mycological Society of America, San Francisco. Sept 9-11, abstract no 16. Med Mycol 2004: 43 (Suppl 1) S1-S319.
65. Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan Program Data from 2003. Antimicrob Agents Chemother 2005; 49: 512-7.
66. Hedayati MT, Pasqualotto AC, Warn PA, Bowyer P, Denning DW. Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 2007; 153: 1677-92.
67. Ozhak-Baysan B, Alastruey-Izquierdo A Saba R, et al. Aspergillus alliaceus and Aspergillus flavus co-infection in an acute myeloid leukemia patient. Med Mycol 2010; 48: 995-9.
68. Gams W, Christensen M, Onions AHS, Pitt JI, Samson RA. Infrageneric taxa of Aspergillus. In Advances in Penicillium and Aspergillus Systematics, pp. 55-61. Edited by Samson RA & Pitt JI. New York: Plenum Press, 1985
69. Pariza MW, Johnson EA. Evaluating the safety of microbial enzyme preparations used in food processing: update for a new century. Regul Toxicol Pharmacol 2001; 33: 173-86.
70. Xu X, Yan M, Zhu Y. Influence of fungal fermentation on the development of volatile compounds in the Pu Erh tea manufacturing. Emg Life Sci 2005; 5: 382-6.
71. Abe M, Takaoka N, Idemoto Y, Takagi C, Imai T, Nakasaki K. Characteristic fungi observed in the fermentation process for Puer tea. Int J Food Microbiol 2008; 124: 199-203.
72. Schuster E, Dunn-Coleman N, Frisvad JC, van Dijck PWM. On the safety of Aspergillus niger-a review. Appl Microbiol Biotechnol 2002; 59: 426-35.
73. Zhao ZJ, Tong HR, Zhou L, Wang EX, Liu QJ. Fungal Colonisation of Pu Erh tea in Yunnan. J Food Safety 2010; 30: 769-84.
74. Schöpfer M, Heiling B, Marth E, Mayr A, Lang-Loidolt D, Buzina W. Aspergillus niger in Otomycosis. Mycoses 2010; 53: 400.
75. Szigeti G, Kocsubé S, Ilona Doczi I, Bereczki L, Vagvölgyi C, Varga J. Molecular identification and antifungal susceptibilities of black Aspergillus isolates from otomycosis cases in Hungary. Mycopathologia 2012; 174: 143-7
76. Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL. Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri. Antimicrob Agents Chemother 2009; 53: 4514-7.
77. Wadhwani K, Srivastava AK. Some cases of onychomycosis from North India in different working environments. Mycopathologia 1985; 92: 149-55.
78. Kano R, Perrone G, Peterson S, et al. Comparative sequence analyses of multiple loci reveal rare Aspergillus species in transplant recipients (TRANSNET study). Abstr 3rd Advances Against Aspergillosis, p 71. Miami 2008.
79. Howard SJ, Harrison E, Bowyer P, Denning DW. Molecular identification of clinical black Aspergillus isolates and azole resistance. Abstr 3rd Advances Against Aspergillosis, p 29. Miami 2008.
80. Kredics L, Varga J, Kocsubé S, et al. Infectious keratitis caused by Aspergillus tubingensis. Cornea 2009; 28: 951-4.
81. Williams B, Popoola B, Ogundana K. A possible new pathogenic Aspergillus isolation and general mycological properties of the fungus. Afr J Med Sci 1984; 13: 111-5.
82. Manikandan P, Varga J, Kocsubé S, et al. Keratitis caused by the recently described new species Aspergillus brasiliensis: two case reports. J Med Case Rep 2010; 4: 68-71.
83. Varga J, Tóth B, Kocsubé S, et al. Evolutionary relationships among Aspergillus terreus isolates and their relatives. Antonie Van Leeuwenhoek 2005; 88: 141-50.
84. Balajee SA. Aspergillus terreus complex. Med Mycol 2009; 47 (Suppl 1): S42-6.
85. Samson RA, Peterson SW, Frisvad JC, Varga J. New species in Aspergillus section Terrei. Stud Mycol 2011; 69: 39-55.
86. Kozakiewicz Z. Aspergillus species on stored products. Mycol Papers 1989; 161: 1-188.
87. Alberts AW, Chen J, Kuron G, et al. Mevinolin-a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme-A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980; 77: 3957-61.
88. Sallam LAR, El-Refai AMH, Hamdy AHA, El-Minofi HA, Abdel-Sallam IS. Role of some fermentation parameters on cyclosporin A production by a new isolate of Aspergillus terreus. J Gen Appl Microbiol 2003; 49: 321-8.
89. Lass-Flörl C, Rath P, Niederwieser D, et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46: 31-5.
90. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infec Dis 2003; 188: 305-19.
91. Balajee SA, Baddley JW, Peterson SW, et al. ISHAM Working Group on A. terreus. Aspergillus alabamensis, a new clinically relevant species in the section Terrei. Eukaryotic Cell 2009; 8: 713-22.
92. Deak E, Nelson M, Hernández-Rodríguez Y, et al. Aspergillus terreus accessory conidia are multinucleated hyperpolarizing structures that display differential dectin staining and can induce heightened inflammatory responses in a pulmonary model of aspergillosis. Virulence 2011; 2: 200-7.
93. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 2003; 41: 5525-9.
94. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-8.
95. Wadhwani K, Srivastava AK. Fungi from otitis media of agricultural field workers. Mycopathologia 1984; 88: 155-9.
96. Auberger J, Lass-Flörl C, Clausen J, et al. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis 2008; 62: 336-9.
97. Morquer R, Enjalbert L. Étude morphologique et physiologique d'un Aspergillus nouvellement isolé au cours d'une affection pulmonaire de l'homme. CR Acad Sci Paris 1957; 244: 1405-8.
98. Barson WJ, Ruymann FB. Palmar aspergillosis in immunocompromised children. Pediatr Infect Dis 1986; 5: 264-8.
99. Tack KJ, Rhame FS, Brown B, Thompson RC. Aspergillus osteomyelitis: report of four cases and review of the literature. Am J Med 1982; 73: 295-300.
100. Katou K, Nanjou K, Kawakami M. A case of chronic necrotizing pulmonary aspergillosis due to Aspergillus flavipes associated with pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi 1999; 37: 938-42.
101. Neuhann T. Clotrimazol in der Behandlung von Keratomykosen. Klin Monatsbl Augenheilkd 1976; 169: 459-62.
102. Peterson SW. Phylogenetic analysis of Aspergillus species using DNA sequences from four loci. Mycologia 2008; 100: 205-26.
103. Peterson SW, Varga J, Frisvad JC, Samson RA. Phylogeny and subgeneric taxonomy of Aspergillus. In: Varga J, Samson RA. Eds. Aspergillus in the genomic era: 33-56. Wageningen: Wageningen Academic Publishers 2008.
104. Varga J, Frisvad JC, Samson RA. Aspergillus sect Aeni sect. nov., a new section of the genus for A. karnatakaensis sp. nov. and some allied fungi. IMA Fungus 2010; 1: 197-205.
105. Frisvad JC, Samson RA. Emericella venezuelensis, a new species with stellate ascospores producing sterigmatocystin and aflatoxin B1. Syst Appl Microbiol 2004; 27: 672-80.
106. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerg Infect Dis 2008; 14: 566-72.
107. Varga J, Houbraken J, Van Der Lee HA, Verweij PE, Samson RA. Aspergillus calidoustus sp. nov. causative agent of human infections previously assigned to Aspergillus ustus. Eukaryot Cell 2008; 7: 630-8.
108. Zalar P, Frisvad JC, Gunde-Cimerman N, Varga J, Samson RA. Four new species of Emericella from the Mediterranean region of Europe. Mycologia 2008; 100: 779-95.
109. Jurjevic Z, Peterson SW, Horn BW. Aspergillus section Versicolores: nine new species and multilocus DNA sequence based phylogeny. IMA Fungus 2012; 3: 59-79.
110. Polacheck I, Nagler A, Okon E, Drakos P, Plaskowitz J, Kwon-Chung KJ. Aspergillus quadrilineatus, a new causative agent of fungal sinusitis. J Clin Microbiol 1992; 30: 3290-3.
111. Gugnani HC, Vijayan YK, Tyagi P, Sharma S, Stchigel AM, Guarro J. Onychomycosis due to Emericella quadrilineata. J Clin Microbiol 2004; 42: 914-6.
112. van der Linden JWM, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol 2011; 49 (Suppl. 1): S82-9.
113. Rippon JW. Medical Mycology-The Pathogenic Fungi and the Pathogenic Actinomycetes. 3rd ed. Philadelphia: Saunders 1988.
114. Schönborn C, Schmoranzer H. Untersuchungen über Schimmelpilzinfektionen der Zehennägel. Mykosen 1970; 13: 253-72.
115. Grigoriu D, Grigoriu A. Les onychomycoses. Rev Méd Suisse Romande 1975; 95: 839-49.
116. Rabinovitch N. Household mold as a predictor of asthma risk: Recent progress, limitations, and future directions. J Allergy Clin Immunol 2012; Jul 31. [Epub ahead of print].
117. Liu Z, Hou T, Shen Q, Liao W, Xu H. Osteomyelitis of sacral spine caused by Aspergillus versicolor with neurologic deficits. Clin Med J 1995; 108: 472-5.
118. Torres-Rodríguez JM, Madrenys Brunet N, Siddat M, López Jodra O, Jimenez T. Aspergillus versicolor as cause of onychomycosis: report of 12 cases and susceptibility testing to antifungal drugs. J Eur Acad Dermatol Venereol 1998; 11: 25-31.
119. Veraldi S, Chiaratti A, Harak H. Onychomycosis caused by Aspergillus versicolor. Mycoses 2010; 53: 363-5.
120. De Amicis E. Clinical mycological and pathogenic observations on three cases of otomycosis with Aspergillus versicolor. Boll Mal Orecch Gola Naso 1950; 68: 278-325.
121. Rotoli M, Sascaro G, Cavalieri S. Aspergillus versicolor infection of the external auditory canal successfully treated with terbinafine. Dermatology 2001; 202: 143.
122. Engelhart SA, Loock D, Skutlarek H, et al. Occurrence of toxigenic Aspergillus versicolor isolates and sterigmatocystin in carpet dust from damp indoor environments. Appl Environ Microbiol 2002; 68:3886-90.
123. Florescu DF, Iwen PC, Hill LA, et al. Cerebral aspergillosis caused by Aspergillus ustus following orthotopic heart transplantation: case report and review of the literature. Clin Transplant 2009; 23: 116-20.
124. Olorunnipa O, Zhang AY, Curtin CM. Invasive Aspergillosis of the Hand Caused by Aspergillus ustus: a Case Report. Hand (NY) 2010; 5: 102-5.
125. Gomes C, Fidel S, Fidel R, de Moura Sarquis MI. Isolation and Taxonomy of Filamentous Fungi in Endodontic Infections. J Endod 2010; 36: 626-9.
126. Samson RA, Houbraken J, Thrane U, Frisvad JC, Andersen B, Eds. Food and indoor fungi. Utrecht: CBS-KNAW Fungal Biodiversity Center 2010.
127. Houbraken J, Due M, Varga J, Meijer M, Frisvad JC, Samson RA. Polyphasic taxonomy of Aspergillus section Usti. Stud Mycol 2007; 59: 107-28.
128. Slack GJ, Puniani E, Frisvad JC, Samson RA, Miller JD. Secondary metabolites from Eurotium species, Aspergillus calidoustus and A. insuetus common in Canadian homes with a review of their chemistry and biological activities. Mycol Res 2009; 113: 480-90.
129. Hageskal G, Kristensen R, Fristad RF, Skaar I. Emerging pathogen Aspergillus calidoustus colonizes water distribution systems. Med Mycol 2011; 49: 588-93.
130. Otčenášek M, Janeckova V, Kaupa R, Medek B, Nevludová D. Ketiologii plicnich aspergilomú. Cesk Epidemiol 1976; 25: 263-8.
131. Fakih MG, Barden GE, Oakes CA, Berenson CS. First reported case of Aspergillus granulosus infection in a cardiac transplant patient. J Clin Microbiol 1995; 33: 471-3.
132. Sutton DA, Wickes BL, Romanelli AM, et al. Cerebral aspergillosis caused by Aspergillus granulosus. J Clin Microbiol 2009; 47: 3386-90.
133. Roussel S, Reboux G, Rognon B, et al. Comparison of three antigenic extracts of Eurotium amstelodami in serological diagnosis of farmer's lung disease. Clin Vaccine Immunol 2010; 17: 160-7.
134. de Bary A. Über die Entwicklung und den Zusammenhang von Aspergillus glaucus und Eurotium. Bot Ztg 1854; 12: 425-34 441-51 465-71.
135. Bereston ES, Waring WS. Aspergillus infection of the nails. Arch Derm Syph Chicago 1946; 54: 552-7.
136. Bambule G, Savary M, Grigoriu D, Delacretaz J. Les otomycoses. Annls Oto-Laryngol 1982; 99: 537-40.
137. Dreizen S, Bodey GP, McCredie KB, Keating MJ. Orofacial aspergillosis in acute leukemia. Oral Surg 1985; 59: 499-504.
138. Traboulsi RS, Kattar MM, Dbouni O, Araj GF, Kanj SS. Fatal brain infection caused by Aspergillus glaucus in an immunocompetent patient identified by sequencing of the ribosomal 18S-28S internal transcribed spacer. Eur J Clin Microbiol Infect Dis 2007; 26: 47-750.
139. Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis. Mycoses 1994; 37: 271-4.
140. Fraga ME, Curvello F, Gatti MJ, Cavaglieri LR, Dalcero AM, da Rocha Rosa CA. Potential aflatoxin and ochratoxin A production by Aspergillus species in poultry feed processing. Vet Res Commun 2007; 31: 343-53.
141. Aznar C, Bièvre C, de Guiguen C. Maxillary sinusitis from Microascus cinereus and Aspergillus repens. Mycopathologia 1989; 105: 93-7.
142. Ishii K, Hitosugi M, Kido M, et al. Analysis of fungi detected in human cadavers. Leg Med (Tokyo) 2006; 8: 188-90.
143. Jones DB. Therapy of postsurgical fungal endophthalmitis. Ophthalmology 1978; 85: 357-73.
144. Mencl K, Otcenásek M, Spacek J, Rehulová E. Aspergillus restrictus und Candida parapsilosis-Erreger von Endokarditiden nach Herzklappentransplantationen. Mykosen 1985; 28: 127-34.
145. Estrader F, Longefait H, Lalaveé G, Coury C, Constans P. Aspergillus restrictus, forme rare d'aspergillome intra-cavitaire associée à une tuberculose active. J Fr Med Chir Thor 1972; 26: 241-9.
146. Varga J, Frisvad JC, Samson RA. Polyphasic taxonomy of Aspergillus section Candidi based on molecular, morphological and physiological data. Stud Mycol 2007; 59: 75-88.
147. Hubka V, Kubatova A, Mallatova N, et al. Rare and new etiological agents revealed among 178 clinical Aspergillus strains obtained from Czech patients and characterized by molecular sequencing. Med Mycol 2012; 50: 601-10.
148. Mortensen KL, Johansen HK, Fuursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011; 30: 1355-63.
149. Staab JF, Kahn JN, Marr KA. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother 2010; 54: 4992-8.
150. Kano R, Shibahashi A, Fujino Y, et al. Two cases of feline orbital aspergillosis due to Aspergillus udagawae and A viridinutans. J Vet Med Sci 2012 Aug 10 [Epub ahead of print].
151. Shigeyasu C, Yamada M, Nakamura N, Mizuno Y, Sato T, Yaguchi T. Keratomycosis caused by Aspergillus viridinutans: an Aspergillus fumigatus-resembling mold presenting distinct clinical and antifungal susceptibility patterns. Med Mycol 2012; 50: 525-8
152. Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011; 54: e583-9.
153. Balajee SA, Lindsley MD, Iqbal N, Ito J, Pappas PG, Brandt ME. Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequencebased methods. J Clin Microbiol 2007; 45: 2701-3.
154. Tokarzewski S, Zió kowska G, Nowakiewicz A. Susceptibility testing of Aspergillus niger strains isolated from poultry to antifungal drugs-a comparative study of the disk diffusion, broth microdilution (M 38-A) and Etest methods. Pol J Vet Sci 2012; 15: 125-33.
155. Hendrickx M, Beguin H, Detandt M. Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM/IHEM collection. Mycoses 2012; 55: 148-55.
156. Sutton DA, Fothergill AW, Rinaldi MG Eds. Guide to Clinically Significant Fungi. Baltimore: Williams Wilkins 1998.
157. Martos AI, Martín-Mazuelos E, Romero A, et al. Evaluation of disk diffusion method compared to broth microdilution for antifungal susceptibility testing of 3 echinocandins against Aspergillus spp. Diagn Microbiol Infect Dis 2012; 73: 53-6.
158. Shi JY, Xu YC, Shi Y, et al. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B, and caspofungin. Chin Med J (Engl) 2010; 123: 2706-9.
159. Alastruey-Izquierdo A, Cuesta M, Houbraken J, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus. Med Mycol 2008; 48: 97-102.
160. Verweij PE, van den Bergh MF, Rath PM, de Pauw BE, Voss A, Meis JF. Invasive aspergillosis caused by Aspergillus ustus: case report and review. J Clin Microbiol 1999; 37: 1606-9.
161. Panackal AA, Imhof A, Hanley EW, Marr KA. Aspergillus ustus infections among transplant recipients. Emerg Infect Dis 2006; 12: 403-8.